Medivir AB (Nasdaq Stockholm: MVIR) today announced safety and efficacy data following an interim analysis of phase I data from the ongoing phase I/II study of birinapant in combination with MSD’s anti-PD-1 therapy, Keytruda® (pembrolizumab), in patients with advanced solid tumors who have exhausted available treatment options. No dose-limiting toxicity has been observed in the first three groups of patients, and the dose escalation has been continued to the highest planned dose level in the study. One of the 12 patients in this interim analysis has had a confirmed partial response to treatment, which means that the dimensions of their tumor were reduced by 30% or more on two consecutive assessments approximately two months apart when compared to the size of the tumor when treatment started.
https://www.prnewswire.com/news-releases/positive-interim-data-on-birinapant-in-combination-with-keytruda-300724304.html
Positive Interim Data on Birinapant in Combination With Keytruda®